רמיקד

Maa: Israel

Kieli: heprea

Lähde: Ministry of Health

Aktiivinen ainesosa:

INFLIXIMAB 100 MG/VIAL

Saatavilla:

J-C HEALTH CARE LTD

ATC-koodi:

L04AA12

Lääkemuoto:

POWDER FOR CONCENTRATE FOR INFUSION

Antoreitti:

I.V

Valmistaja:

JANSSEN BIOLOGICS, BV, THE NETHERLAND

Terapeuttinen ryhmä:

INFLIXIMAB

Käyttöaiheet:

- Adult :Crohn's disease: Treatment of severe active Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -Paediatric Crohn's disease: Remicade is indicated for: Treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy -Ankylosing spondylitis: Remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther

Valtuutus päivämäärä:

2010-01-01